Abstract

Background With the traditional FDA approval of lecanemab for treatment of early symptomatic Alzheimer disease (AD), there has been a surge in demand for clinical AD biomarker testing. While amyloid PET, cerebrospinal fluid (CSF) biomarkers, and AD blood tests are all clinically available, each have different benefits and limitations affecting their real‐world use.
Methods Pragmatic issues affecting usage of different AD biomarker testing modalities...